These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 782963)

  • 1. Experience of nasal application of inactivated influenza vaccine.
    Fukumi H
    Dev Biol Stand; 1976; 33():155-61. PubMed ID: 782963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials with intranasally administered WRL 105 strain live influenza vaccine in volunteers.
    Freestone DS
    Dev Biol Stand; 1976; 33():207-12. PubMed ID: 782971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of an inhibitor-resistant live attenuated influenza vaccine in normal and asthmatic adults.
    Warshauer DM; Minor TE; Inhorn SL; Reed CE; Dick EC
    Dev Biol Stand; 1976; 33():184-90. PubMed ID: 782967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Criteria in the evaluation of live intranasal influenza virus vaccines.
    Zygraich N
    Dev Biol Stand; 1976; 33():141-50. PubMed ID: 782962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of live attenuated influenza vaccine ts-1(E) in man.
    Gwaltney JM
    Dev Biol Stand; 1976; 33():178-83. PubMed ID: 782966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural challenge of subjects vaccinated with WRL 105 strain live influenza vaccine in a residential community.
    Morris CA; Freestone DS; Stealey VM
    Dev Biol Stand; 1976; 33():197-201. PubMed ID: 782969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G; Greenbaum E; Zakay-Rones Z
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of peroral and intranasal immunization of school children with live allantoic influenza vaccine- and comparative study.
    Koval TA; Aleksandrova GI; Grunis AM; Ivannikov YuG ; Medvedeva TE; Sychev SV; Shaposhnikova RP; Smorodintsev AA
    J Hyg Epidemiol Microbiol Immunol; 1979; 23(2):194-200. PubMed ID: 395255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary results of oral influenza vaccination with live attenuated viruses.
    DeBarbieri A; Crovari P; Cuneo-Crovari P; Badolati G; Giacometti G
    Dev Biol Stand; 1976; 33():213-9. PubMed ID: 782972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live attenuated influenza vaccine in children.
    Ambrose CS; Walker RE; Connor EM
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):206-12. PubMed ID: 17055372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity to influenza in older adults with chronic obstructive pulmonary disease.
    Gorse GJ; O'Connor TZ; Newman FK; Mandava MD; Mendelman PM; Wittes J; Peduzzi PN
    J Infect Dis; 2004 Jul; 190(1):11-9. PubMed ID: 15195238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness.
    Hurwitz ES; Haber M; Chang A; Shope T; Teo ST; Giesick JS; Ginsberg MM; Cox NJ
    J Infect Dis; 2000 Oct; 182(4):1218-21. PubMed ID: 10979921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of live recombinant influenza vaccine.
    Stealey VM; McCahon D; Freestone DS
    Dev Biol Stand; 1976; 33():191-6. PubMed ID: 955267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of inactivated influenza vaccine in children.
    Wright PF
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):200-5. PubMed ID: 17055371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.